ni2o Inc.

A spinout of Oxford University, founded by a global team of experienced entrepreneurs, technologists, and neuroscientists, ni2o is continuing the work started by MIT’s Mind Machine Project – developing a revolutionary brain-computer interface (BCI) that addresses the most pressing and costly medical needs of a rapidly aging global population, the treatment of neurodegenerative brain diseases and disorders.

We strive to restore human dignity to patients who suffer with debilitating brain diseases and disorders by restoring their abilities. We believe the world will be faced with unsustainable costs and burdens on society to adequately care for the growing and aging population with the dignity they deserve.

We begin by attacking the debilitating affliction of Parkinson’s Disease. Today, of the estimated 10 million people globally suffering with Parkinson’s, there are three proven deep brain stimulation (DBS) treatments on the market. However, they all require up to a 12-hour surgery, holes drilled into the skull, wires run through the neck to an implanted device in the chest, all coupled with potentially significant complications. Our minimally-invasive implant, KIWI, will change all of this.

After we conquer Parkinson’s disease, we then turn our focus to Alzheimer’s disease.